Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...

The lower rating came from HSBC, which cited too much optimism around its new weight-loss pill, and the strength of Novo ...

Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate ...

Mounjaro, the new weight loss drug, is gaining popularity in India for its rapid results. Patients report better appetite control, blood sugar management, and significant weight loss.

With its 2-star rating, we believe Lilly stock is overvalued compared with our long-term fair value estimate of $650 per ...

Approved by India’s apex drug regulatory body, the weight-loss drug is a once-weekly injection priced at Rs 4,375 for a 5 mg ...